Background: It was the aim of this study to compare the repeatability of Spectralis optical coherence tomography (OCT) retinal thickness measurements in healthy subjects and diabetic patients with clinically significant macular edema (CSME) with or without the use of the follow-up system. Methods: Thirty-eight eyes of 38 healthy subjects (control group) and 68 eyes of 68 diabetic patients with CSME were included in the study. The coefficient of repeatability (CR) and intrasession coefficients of variation were tested with 20 × 15 degree raster scans consisting of 19 high-resolution line scans (15 frames per scan) that were repeated 3 times by 1 experienced examiner. The first scan was set as the reference scan, whereas the second and third scans were the follow-up scans and were performed with and without the use of the follow-up mode, respectively. Results: The means and standard deviations for the central foveal subfield (CSF) in healthy subjects and diabetic patients were 289 ± 21 and 402 ± 105 μm, respectively. Particularly in diabetic patients, examining the CSF, CR was 2.67% (10.73 µm) and 6.73% (27.01 µm) with and without using the follow-up mode, respectively, and the difference was statistically significant (p < 0.05). Conclusion: These results support the hypothesis that the follow-up system improves the repeatability either in healthy subjects or in diabetic patients with poor fixation. The wider improvement in repeatability in diabetic patients in the follow-up system group compared to the no follow-up system group are probably related to poor patient fixation or eye movement in patients with CSME.

Keywords:
Optical coherence tomography, Spectralis, Diabetic macular edema
1.
Jaffe GJ, Caprioli J: Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol 2004;137:156-169.
2.
Otani T, Kishi S, Maruyama Y: Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999;127:688-693.
3.
Haouchine B, Massin P, Tadayoni R, et al: Diagnosis of macular pseudoholes and lamellar macular holes by optical coherence tomography. Am J Ophthalmol 2004;138:732-739.
4.
Sanchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, et al: Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002;43:1588-1594.
5.
Politoa A, Napolitano MC, Bandello F, et al: The role of optical coherence tomography (OCT) in the diagnosis and management of retinal angiomatous proliferation (RAP) in patients with age-related macular degeneration. Ann Acad Med Singapore 2006;35:420-424.
6.
Massin P, Vicaut E, Haouchine B, et al: Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 2001;119:1135-1142.
7.
Polito A, Del Borrello M, Isola M, et al: Repeatability and reproducibility of fast macular thickness mapping with stratus optical coherence tomography. Arch Ophthalmol 2005;123:1330-1337.
8.
Danis RP, Fisher MR, Lambert E, et al: Results and repeatability of retinal thickness measurements from certification submissions. Arch Ophthalmol 2008;126:45-50.
9.
Krzystolik MG, Strauber SF, Aiello LP, et al: Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 2007;114:1520-1525.
10.
Wojtkowski M, Srinivasan V, Fujimoto JG, et al: Three-dimensional retinal imaging with high-speed ultra-high resolution optical coherence tomography. Ophthalmology 2005;112:1734-1746.
11.
Alam S, Zawadzki RJ, Choi S, et al: Clinical application of rapid serial Fourier-domain optical coherence tomography for macular imaging. Ophthalmology 2006;113:1425-1431.
12.
Hangai M, Ojima Y, Gotoh N, et al: Three-dimensional imaging of macular holes with high-speed optical coherence tomography. Ophthalmology 2007;114:763-773.
13.
Ojima Y, Hangai M, Sasahara M, et al: Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography. Ophthalmology 2007;114:2197-2207.
14.
Ahlers C, Michels S, Beckendorf A, et al: Three-dimensional imaging of pigment epithelial detachment in age-related macular degeneration using optical coherence tomography, retinal thickness analysis and topographic angiography. Graefes Arch Clin Exp Ophthalmol 2006;244:1233-1239.
15.
Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
16.
Browning DJ, Glassman AR, Aiello LP, et al; Diabetic Retinopathy Clinical Research Network: Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 2008;115:1366-1371, 1371.e1.
17.
Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
18.
Comyn O, Heng LZ, Ikeji F, Bibi K, Hykin PG, Bainbridge JW, Patel PJ: Repeatability of Spectralis OCT measurements of macular thickness and volume in diabetic macular edema. Invest Ophthalmol Vis Sci 2012;53:7754-7759.
19.
Fiore T, Androudi S, Iaccheri B, Lupidi M, Giansanti F, Fruttini D, Biondi L, Cagini C: Repeatability and reproducibility of retinal thickness measurements in diabetic patients with spectral domain optical coherence tomography. Curr Eye Res 2013;38:674-679.
20.
Paunescu LA, Schuman JS, Prince LL, et al: Reproducibility of nerve fiber thickness, macular thickness, and optic nerve head measurements using Stratus OCT. Invest Ophthalmol Vis Sci 2004;45:1716-1724.
21.
Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT: Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci 2008;49:4290-4296.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.